Filtered By:
Condition: Thrombosis
Management: WHO

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 37 results found since Jan 2013.

What Causes Microcephaly?
Discussion Microcephaly is usually defined as an occipitofrontal head circumference (OFC) more than 2 standard deviations (SD) below the mean for sex, age and ethnicity. Severe microcephaly is used for OFC < 3 standard deviations. Rates of microcephaly range from 0.5-12 patients/10,000 live births. The OFC should be measured at every well child visit and at other opportunities and plotted on standard growth charts. The OFC is measured using a nonelastic tape measure around the largest part of the head with the tape measure held above the eyebrows and ears. It is a highly reproducible measurement. There are several diff...
Source: PediatricEducation.org - September 25, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Long-Term Outcomes in Patients with Anemia And Cerebral Venous Thrombosis
ConclusionsAnemia was a significant and independent predictor of unfavorable functional outcome in patients with CVT.
Source: Neurocritical Care - July 9, 2018 Category: Neurology Source Type: research

Thrombolytic therapy for pulmonary embolism.
CONCLUSIONS: Low-quality evidence suggests that thrombolytics reduce death following acute pulmonary embolism compared with heparin. The included studies used a variety of thrombolytic drugs. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause major and minor haemorrhagic events and stroke. More high-quality, blinded randomised controlled trials assessing safety and cost-effectiveness of therapies for pulmonary embolism are required. PMID: 30560579 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 18, 2018 Category: General Medicine Authors: Hao Q, Dong BR, Yue J, Wu T, Liu GJ Tags: Cochrane Database Syst Rev Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research

Antiplatelet agents and anticoagulants for hypertension
CONCLUSIONS: There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events. Antiplatelet therapy with ASA probably reduces the risk of non-fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention. There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention. The benefits and harms of the newer dr...
Source: Cochrane Database of Systematic Reviews - July 28, 2022 Category: General Medicine Authors: Eduard Shantsila Monika Kozie ł-Siołkowska Gregory Yh Lip Source Type: research

Acute Occupational and Physical Therapy for COVID-19 Patients: A Retrospective Cohort Study
In March 2020, the World Health Organization (WHO) declared the novel coronavirus strain SARS-CoV2 (the virus causing COVID-19) a global pandemic.24 The severity of illness in those exhibiting symptoms ranges from mild (cough, shortness of breath, fatigue) to severe (acute respiratory distress syndrome (ARDS), thrombosis, stroke, and death).4,11 Patients have also acquired acute polyradiculoneuritis (Guillain Barre syndrome) at a disproportionately high rate, contributing to functional limitations that require specialized and intensive rehabilitation.
Source: Archives of Physical Medicine and Rehabilitation - July 31, 2022 Category: Rehabilitation Authors: Katie Coakley, Laura Friedman, Kaitlyn McLoughlin, Amy Wozniak, Paul Hutchison Tags: Original Research Source Type: research